The Role of Immunotherapy in Managing Lung Diseases: Current Trends and Future Directions

Tung Gurra^*
*Correspondence: Tung Gurra, Department of Pulmonary, Critical Care Medicine, Texas A&M University, College Station, TX 77845, USA, Email:

Keywords

Immunotherapy • Lung diseases • Asthma • COPD • Lung cancer

Introduction

Lung diseases represent a significant public health burden, with a wide range of conditions that affect the respiratory system, including asthma, chronic obstructive pulmonary disease (COPD) and lung cancer. These diseases can lead to reduced quality of life and, in some cases, are life-threatening. While conventional therapies have been the mainstay of treatment for many years, recent advances in immunotherapy have opened up new avenues for managing lung diseases. Immunotherapy, a treatment that harnesses the body's immune system to fight diseases, has shown promising results in various cancers and autoimmune disorders. This article explores the current trends and future directions of immunotherapy in managing lung diseases, with a particular focus on asthma, COPD and lung cancer. Immunotherapy is a groundbreaking approach to managing lung diseases that leverages the body's immune system to combat the underlying causes of these conditions. Unlike traditional treatments, which often focus on symptom management, immunotherapy aims to modify the immune response to prevent and treat lung diseases more effectively [1].

Literature Review

Asthma is a chronic respiratory disease characterized by airway inflammation and bronchoconstriction. While inhaled corticosteroids and bronchodilators are the primary treatments, some severe cases are refractory to these therapies. Immunotherapy for asthma involves the use of monoclonal antibodies that target specific immune pathways, such as Interleukin-5 (IL-5) and Immunoglobulin E (IgE). Monoclonal antibodies, such as omalizumab and mepolizumab, have shown significant efficacy in reducing asthma exacerbations and improving lung function in individuals with severe asthma. These drugs work by modulating the immune system's response, reducing inflammation and decreasing the frequency and severity of asthma attacks. The success of these treatments has prompted ongoing research to identify new targets and further refine immunotherapy for asthma [2].

COPD is a progressive lung disease characterized by chronic inflammation and airflow limitation. Smoking is a leading cause of COPD and it is a major global health problem. Traditional treatments for COPD primarily focus on symptom relief and slowing disease progression. However, immunotherapy for COPD is an emerging field that offers the potential to modify the course of the disease. One avenue of research involves therapeutic vaccines that target specific proteins or antigens related to COPD pathogenesis. These vaccines aim to stimulate the immune system to recognize and neutralize harmful molecules and cells involved in COPD. Additionally, immune checkpoint inhibitors, which have shown promise in cancer therapy, are being explored for their potential in COPD management. Lung cancer is one of the deadliest forms of cancer, with a high mortality rate. While surgical resection, chemotherapy and radiation therapy have been the mainstays of lung cancer treatment, immunotherapy has revolutionized the field of oncology in recent years. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have demonstrated impressive results in treating advanced Non-Small Cell Lung Cancer (NSCLC) [3].

These drugs work by blocking specific immune checkpoint proteins that inhibit T-cell activity, enabling the immune system to recognize and attack cancer cells. Immunotherapy for lung cancer has significantly improved the survival rates of patients with advanced disease and has led to long-term remissions in some cases. The current trends in immunotherapy for lung diseases are promising, but ongoing research and developments are shaping the future of this field. One of the most exciting aspects of future immunotherapy for lung diseases is personalized medicine. With advances in genomics and molecular profiling, clinicians can tailor treatment approaches to individual patients based on their genetic and immunological profiles. Personalized immunotherapy is expected to enhance treatment effectiveness, minimize side effects and optimize patient outcomes [4].

Discussion

One of the primary challenges of immunotherapy is its cost. Many immunotherapeutic agents are expensive, making them inaccessible to a significant portion of the population. Addressing the cost barrier is crucial to ensure that these cutting-edge treatments are available to all patients who may benefit from them. Healthcare systems and pharmaceutical companies need to work together to develop more affordable options or establish reimbursement strategies that make immunotherapy more accessible. Immunotherapy can cause side effects, including immune-related adverse events (irAEs). These side effects can affect various organ systems and vary in severity. Common irAEs include skin rashes, colitis and endocrine abnormalities. While most irAEs are manageable, severe cases can be life-threatening. Clinicians need to be well-prepared to monitor and manage these side effects to ensure patient safety [5].

Not all patients respond equally to immunotherapy and identifying predictive factors for treatment response is a complex challenge. Research is ongoing to determine biomarkers and genetic factors that can help clinicians select the most appropriate candidates for immunotherapy. This personalized approach could minimize ineffective treatments and potential side effects, enhancing the overall effectiveness of the therapy. While immunotherapy has made significant strides in treating lung cancer, its potential in other lung diseases, such as asthma and COPD, is still being explored. Developing therapies tailored to these conditions, understanding the underlying mechanisms and identifying appropriate targets are essential for broadening the application of immunotherapy in lung disease management [6].

Conclusion

Immunotherapy is ushering in a new era in the management of lung diseases, offering the potential for more effective and targeted treatments. Current trends in immunotherapy for lung diseases, including asthma, COPD and lung cancer, are showing promising results and ongoing research is shaping the future of this field. Personalized medicine, combination therapies, early intervention and the extension of immunotherapy to rare lung diseases are key areas of development. While challenges remain, the potential benefits in terms of improved patient outcomes and quality of life make immunotherapy a field of great promise for the future of lung disease management.

In the years to come, immunotherapy for lung diseases will continue to evolve, offering new possibilities for prevention, early intervention and the effective management of these conditions. As our understanding of the immune system and disease mechanisms deepens, we can anticipate innovative therapies that transform the landscape of lung disease treatment, providing hope for a healthier future for those affected by these conditions. The future of immunotherapy for lung diseases holds even more promise, with advancements in personalized medicine, combination therapies, early intervention and extending its application to rare lung diseases.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Osmani, Lais, Frederic Askin, Edward Gabrielson and Qing Kay Li. "Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of Non-Small Cell Lung Carcinoma (NSCLC): Moving from targeted therapy to immunotherapy." Semin Cancer Biol 52 (2018): 103-109

Google Scholar, Crossref, Indexed at

2. Ruiz-Cordero, Roberto and Walter Patrick Devine. "Targeted therapy and checkpoint immunotherapy in lung cancer." Surg Pathol Clin 13 (2020): 17-33.

Google Scholar, Crossref, Indexed at

3. Mielgo-Rubio, Xabier, Eider Azkona Uribelarrea, Laura Quintanta Cortés and María Sereno Moyano. "Immunotherapy in non-small cell lung cancer: Update and new insights." Clin Transl Sci 7 (2021): 1.

Google Scholar, Crossref, Indexed at

4. Ortega-Franco, Ana, Clare Hodgson, Haseem Raja and Mathew Carter, et al. "Real-world data on pembrolizumab for pretreated non-small-cell lung cancer: Clinical outcome and relevance of the lung immune prognostic index." Target Oncol 17 (2022): 453-465.

Google Scholar, Crossref, Indexed at

5. Jones, Mark R., Oliver Morgan Hall, Adam M. Kaye and Alan David Kaye. "Drug-induced acute pancreatitis: A review." Ochsner J 15 (2015): 45-51.

Google Scholar, Indexed at

6. Weissmann, Thomas, Daniel Höfler, Markus Hecht and Sabine Semrau, et al. "Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?." Radiat Oncol 16 (2021): 1-10.

Google Scholar, Crossref, Indexed at